Zoetis Inc. (NYSE:ZTS) Shares Sold by Mairs & Power Inc.

Mairs & Power Inc. lessened its holdings in shares of Zoetis Inc. (NYSE:ZTSGet Rating) by 9.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,550 shares of the company’s stock after selling 154 shares during the period. Mairs & Power Inc.’s holdings in Zoetis were worth $292,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of ZTS. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its position in Zoetis by 430.8% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after purchasing an additional 112 shares in the last quarter. Worth Asset Management LLC purchased a new stake in Zoetis during the first quarter worth $26,000. Financial Management Professionals Inc. boosted its position in Zoetis by 117.4% during the first quarter. Financial Management Professionals Inc. now owns 150 shares of the company’s stock worth $28,000 after purchasing an additional 81 shares in the last quarter. Hanson & Doremus Investment Management boosted its position in Zoetis by 713.6% during the first quarter. Hanson & Doremus Investment Management now owns 179 shares of the company’s stock worth $34,000 after purchasing an additional 157 shares in the last quarter. Finally, City State Bank purchased a new stake in Zoetis during the fourth quarter worth $36,000. 91.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Stifel Nicolaus decreased their target price on Zoetis from $275.00 to $225.00 and set a “buy” rating on the stock in a research report on Friday, June 24th. Piper Sandler began coverage on Zoetis in a research report on Monday, July 11th. They issued an “overweight” rating and a $205.00 price objective on the stock. William Blair restated an “outperform” rating on shares of Zoetis in a research report on Friday, August 5th. StockNews.com upgraded Zoetis from a “buy” rating to a “strong-buy” rating in a research report on Friday. Finally, The Goldman Sachs Group reduced their price objective on Zoetis from $208.00 to $202.00 and set a “buy” rating on the stock in a research report on Thursday, July 21st. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $224.00.

Zoetis Stock Performance

NYSE ZTS opened at $164.31 on Friday. The business’s 50-day moving average price is $170.78 and its 200 day moving average price is $175.69. Zoetis Inc. has a twelve month low of $154.18 and a twelve month high of $249.27. The company has a market capitalization of $76.92 billion, a PE ratio of 37.26, a price-to-earnings-growth ratio of 2.87 and a beta of 0.77. The company has a current ratio of 2.18, a quick ratio of 1.46 and a debt-to-equity ratio of 1.14.

Zoetis (NYSE:ZTSGet Rating) last released its earnings results on Thursday, August 4th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.22 by ($0.02). Zoetis had a return on equity of 49.03% and a net margin of 26.14%. The business had revenue of $2.10 billion for the quarter, compared to analysts’ expectations of $2.03 billion. During the same quarter last year, the company posted $1.19 earnings per share. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, research analysts predict that Zoetis Inc. will post 5.01 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 2,167 shares of the stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $180.26, for a total transaction of $390,623.42. Following the transaction, the executive vice president now directly owns 23,687 shares in the company, valued at $4,269,818.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Roxanne Lagano sold 2,167 shares of the stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $180.26, for a total transaction of $390,623.42. Following the transaction, the executive vice president now directly owns 23,687 shares in the company, valued at $4,269,818.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kristin C. Peck sold 9,689 shares of the company’s stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of $180.00, for a total value of $1,744,020.00. Following the sale, the chief executive officer now owns 39,743 shares of the company’s stock, valued at $7,153,740. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,501 shares of company stock worth $2,949,073. 0.12% of the stock is owned by company insiders.

Zoetis Company Profile

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Read More

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSGet Rating).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.